 AUSTIN, Texas, March 31, 2021 PRNewswire -- VolitionRx Limited NYSE AMERICAN: VNRX Volition, a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the publication in Scientific Reports of a paper entitled A Novel Proteomics Approach to Epigenetic Profiling of Circulating Nucleosomes . Dr. Marielle Herzog, lead author of the paper and Volitions Research and Development Director, commented, Our novel method detects and quantifies histone modifications present in the circulating nucleosomes in the blood of cancer patients. 